Identification of Jaundice in Newborns Using Smartphones

Sponsor
St. Olavs Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04182555
Collaborator
Norwegian University of Science and Technology (Other), Helse Fonna (Other)
200
2
1
25.4
100
3.9

Study Details

Study Description

Brief Summary

Neonatal jaundice is a common and most often harmless condition. However, when unrecognized it can be fatal or cause serious brain injury. Three quarters of these deaths are estimated to occur in the poorest regions of the world. The treatment of jaundice, phototherapy, is in most cases easy, low-cost and harmless. The crucial point in reducing the burden of disease is therefore to identify then children at risk. This results in the need for low-cost, reliable and easy-to-use diagnostic tools that can identify newborns with jaundice.

Based on previous research on the bio-optics of jaundiced newborn skin, a prototype of a smartphone application was developed and tested in a pilot study and the application refined.

This smartphone application will now be evaluated in a clinical trial set in two hospitals in Norway. The smartphone application gives immediate estimates of bilirubin values in newborns, and these estimates will be compared to the bilirubin levels measured in standard blood samples, as well as the results from ordinary transcutaneous measurement devices.

Condition or Disease Intervention/Treatment Phase
  • Device: Bilirubin estimates from Smartphone Application
  • Diagnostic Test: Bilirubin concentration measured in standard blood samples
  • Device: Bilirubin estimates from standard transcutaneous device
  • Other: Visual assessment of jaundice
N/A

Detailed Description

The smartphone jaundice app system works by taking pictures of newborns with a custom-made color calibration card placed on their chest. This makes it possible to measure the skin color precisely regardless of the specific light source that is used to illuminate the newborn. The measured skin color is then compared with items in a database of simulated newborn skin colors. These simulated newborn skin colors have been created using numerical simulations of how light moves through skin, with varying skin parameters including, but not limited to, skin thickness, blood concentration, melanin, and of course bilirubin, the pigment that causes jaundice. By comparing the measured skin color with the simulated skin colors that are most similar to it, the investigators can then estimate the bilirubin concentration in the newborn's skin by e.g. averaging the bilirubin concentrations used to create these simulated skin colors.

In a group of 200 newborns with varying degree of jaundice, correlation between smartphone bilirubin estimates will be compared with total serum bilirubin and standard transcutaneous bilirubinometry.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
200 newborns with varying degree of jaundice will be recruited.200 newborns with varying degree of jaundice will be recruited.
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Identification of Jaundice in Newborns Using Smartphones
Actual Study Start Date :
Aug 3, 2020
Anticipated Primary Completion Date :
Sep 15, 2022
Anticipated Study Completion Date :
Sep 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Newborns in St.Olavs Hospital and Haugesund Hospital

All newborns will be examined through 4 different methods of determining jaundice.

Device: Bilirubin estimates from Smartphone Application
Bilirubin estimates through color analysis of digital images obtained through smartphone application.

Diagnostic Test: Bilirubin concentration measured in standard blood samples
Bilirubin measured in total serum bilirubin.

Device: Bilirubin estimates from standard transcutaneous device
Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)

Other: Visual assessment of jaundice
Degree of jaundice will be assessed by Kramer scale

Outcome Measures

Primary Outcome Measures

  1. Smartphone application sensitivity [5 minutes]

    Sensitivity of the smartphone application to detect severe jaundice, defined as total serum bilirubin value > 250 umol/l.

Secondary Outcome Measures

  1. Repeatability [5 min]

    To evaluate the repeatability of multiple measurements with the new smartphone tool

  2. Correlation between bilirubin estimates by smartphone pictures and by total serum bilirubin [5 minutes]

    Estimate of bilirubin levels from smartphone pictures, compared with bilirubin measurements in total serum. Correlation will be expressed by Pearson correlation coefficient, r.

  3. Correlation between bilirubin estimates by smartphone pictures and by standard transcutaneous readings. [5 minutes]

    To evaluate the correlation between bilirubin estimates from a smartphone application and bilirubin estimates from a standard transcutaneous device in newborns with varying degree of jaundice. Correlation will be expressed by Pearson correlation coefficient, r.

  4. Correlation between bilirubin estimates by smartphone pictures and visual assessment of jaundice [5 min]

    - To evaluate the correlation between bilirubin estimates from a smartphone application and bilirubin estimates from visual inspection in newborns with varying degree of jaundice

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Day to 14 Days
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Born in St.Olavs hospital, Trondheim or in Haugesund Hospital, Norway

  • Born with gestational age >36+6

  • Birth weight ≥ 2500g and <4500g

  • Age 1 - <15 days

  • Are having a blood sample performed, as newborn screening or for jaundice assessment

Exclusion criteria:
Infants needing intensive treatment. This includes:
  • Infants in the need for respiratory support

  • Infants with conditions that could compromise skin circulation, as sepsis, heart failure or other

  • Infants that have received phototherapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Haugesund Hospital Haugesund Norway
2 St Olavs Hospital Trondheim Norway

Sponsors and Collaborators

  • St. Olavs Hospital
  • Norwegian University of Science and Technology
  • Helse Fonna

Investigators

  • Study Director: Siri Forsmo, md prof, Norwegian University of Science and Technology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
St. Olavs Hospital
ClinicalTrials.gov Identifier:
NCT04182555
Other Study ID Numbers:
  • 2018/1608
First Posted:
Dec 2, 2019
Last Update Posted:
Aug 23, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by St. Olavs Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2021